Cretostimogene plus pembrolizumab created strong finish responses in patients with BCG-unresponsive nonmuscle-invasive bladder cancer. Use regimen with caution in patients with HIV and/or cavitary condition. skipped doses can lead to therapy failure, relapse, and purchased drug resistance. TB ailm